SCHEMBL4386613

SCHEMBL4386613

Nc1ccc(Sc2ccc(O)cc2)c(N)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE7A Q13946 5/20 0.52
NR1H2 P55055 1/20 0.48
ALDH1A1 P00352 6/20 0.44
CYP3A4 P08684 3/20 0.44
ALOX15 P16050 2/20 0.44
HSD17B10 Q99714 2/20 0.44
CASP1 P29466 2/20 0.44
CA14 Q9ULX7 2/20 0.44
CA3 P07451 1/20 0.44
THRB P10828 1/20 0.44
CA6 P23280 1/20 0.44
HIF1A Q16665 1/20 0.44
MAPK1 P28482 2/20 0.43
TSHR P16473 1/20 0.43
HPGD P15428 6/20 0.42
KDM4E B2RXH2 5/20 0.42
MAPT P10636 5/20 0.42
CYP2C19 P33261 2/20 0.42
MEN1 O00255 1/20 0.42
CYP1A2 P05177 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1454650 0.88 NR1H2 (0.52) PDE7ANR1H2ALDH1A1CYP3A4ALOX15
SCHEMBL810973 0.81 NR1H2 (0.45) PDE7ANR1H2ALDH1A1ALOX15HSD17B10
SCHEMBL809598 0.81 ALDH1A1 (0.54) NR1H2ALDH1A1CYP3A4ALOX15HSD17B10
SCHEMBL9631752 0.80 ALDH1A1 (0.61) PDE7AALDH1A1CYP3A4ALOX15HSD17B10
SCHEMBL810511 0.79 SLC6A2 (0.49) PDE7ANR1H2ALDH1A1ALOX15HSD17B10
SCHEMBL30565314 0.79 ITGB2 (0.48) PDE7AALDH1A1CYP3A4CASP1MAPK1
SCHEMBL9346269 0.79 ITGB2 (0.48) PDE7AALDH1A1CYP3A4CASP1MAPK1
SCHEMBL19041461 0.78 CYP3A4 (0.61) PDE7AALDH1A1CYP3A4ALOX15HSD17B10
SCHEMBL4386608 0.78 KDM4E (0.54) NR1H2ALDH1A1ALOX15HSD17B10MAPK1
SCHEMBL719040 0.77 CYP3A4 (0.74) PDE7ANR1H2ALDH1A1CYP3A4ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8236950-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2012-08-07 US disclosed
EP-2094276-A2 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2009-09-02 EP disclosed
WO-2008133753-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2008-11-06 WO disclosed
EP-1979348-A2 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-10-15 EP disclosed
US-20070232627-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-10-04 US disclosed
WO-2007076034-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232627-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 PDE7A 4223/4885NR1H2 221/4885ALDH1A1 2723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.